Loss of E-cadherin membranous expression was observed in 61/105 (58%) OSCCs (Table 1, Figure 1D) and was associated with late clinical stage (p = 0.006, OR = 3.1, 95% C.I = 1.3–7.0), increased tumor burden (p = 0.03; OR = 2.4, 95% C.I. = 1.1–5.3), and nodal metastasis (p = 0.04; OR = 2.4, 95% C.I. = 1.1–5.3). Here, CDH1 is linked to neoplasm.